Professor, Medicine, Loyola University of Chi Stritch School of Medicine
Infectious Disease
Dr. Stuart B. Johnson, MD
|
|
Give Review
Dr. Stuart B. Johnson works in the field of Infectious Disease. He researched medicine at University of Minnesota Medical School. University of Minnesota Medical School has a rank of 40 in research and a 10 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification". Doctor Stuart B. Johnson, MD is also a published MD. He has 63 publication published. The most recent publication is: Myocardial lipid composition in turkeys with dilated cardiomyopathy. Dr. Stuart B. Johnson accepts Medicare payments and is listed with Medicare.gov.
Publications
- Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection (CDI) with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Str...
- Treatment of Clostridium difficile infections.
- Clostridium difficile Infection (CDI) Severity and Outcome among Patients Infected with the NAP1/BI/027 Strain in a Non-Epidemic Setting.
- Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.
- Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results from Two Multinational, Randomized, Controlled Trials.
- Community-Associated Clostridium difficile Infection among Veterans with Spinal Cord Injury and Disorder.
- Changing Epidemiology of C. difficile and Emergence of New Virulent Strains.
- Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder.
- Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance.
- Antibiotic prescribing trends in the emergency department for veterans with spinal cord injury and disorder 2002-2007.
- Non-Toxigenic Clostridium difficile Protects Hamsters Against Challenge with Historic and Epidemic Toxigenic BI/NAP1/027 C. difficile.
- Does infection with Specific Clostridium difficile Strains or Clades Influence Clinical Outcome?
- Effectiveness of Hand Hygiene for Removal of Clostridium difficile Spores from Hands.
- Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy.
- Important clinical advances in the understanding of Clostridium difficile infection.
- Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
- Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea.
- Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain.
- Meeting the challenge of recurrent Clostridium difficile infection.
- Enteric infections.
- Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection.
- Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration.
- Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals.
- In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
- Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.
- Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins.
- International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants.
- Colonization for the prevention of Clostridium difficile disease in hamsters.
- Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
- Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands.
- Introduction to the special issue on Clostridium difficile.
- Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain.
- New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.
- Toxin B is essential for virulence of Clostridium difficile.
- Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colo...
- Clostridium difficile Outbreak Strain BI Is Highly Endemic in Chicago Area Hospitals.
- Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
- Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI.
- Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
- Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis,...
- Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007.
- Revised nomenclature of Clostridium difficile toxins and associated genes.
- Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital.
- Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital.
- Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure.
- Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.
- Infection of hamsters with historical and epidemic BI types of Clostridium difficile.
- Predominance of a single restriction endonuclease analysis group with intrahospital subgroup diversity among Clostridium difficile isolates at two Chicago hospitals.
- An epidemic, toxin gene-variant strain of Clostridium difficile.
- Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
- Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restric...
- Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system.
- Measuring the severity of Clostridium difficile infection: implications for management and drug development.
- Toxinotype V Clostridium difficile in humans and food animals.
- Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clos...
- Management of Clostridium difficile infection: thinking inside and outside the box.
- Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.
- Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital.
- Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious...
- Clostridium difficile-associated disease treatment response depends on definition of cure.
- Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases.
- Myocardial lipid composition in turkeys with dilated cardiomyopathy.
Schools
University of Mn Med Sch
University Of Minnesota
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Minnesota at Fairview -
University of Minnesota Medical School
Hospital
-
Sarah Bush Lincoln Health Center
Drug Facts
| NPI NUMBER | 1184601452 | |
| NPPES Provider LastName | JOHNSON | |
| NPPES Provider FirstName | STUART | |
| NPPES Provider ZIPCode | 60153 | |
| NPPES Provider State | IL | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 42.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184601452 |
| Last Name Of The Provider | JOHNSON |
| First Name Of The Provider | STUART |
| View All |
Similar Doctors
|
|
Dr. Andrea R. Norris, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nina M. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Negar N. Alami, MD |
|
|
Dr. David Hecht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gail E. Reid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan Pacheco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dale N. Gerding, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jorge Parada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip B. Antiporta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Krutika Kuppalli, MD
This Doctor is OpenDoctor Recommended.
|